Evanson Asset Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,495 shares of the company’s stock after acquiring an additional 315 shares during the quarter. Evanson Asset Management LLC’s holdings in Johnson & Johnson were worth $2,923,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $4,172,929,000. BlackRock Inc. increased its stake in shares of Johnson & Johnson by 2.6% in the fourth quarter. BlackRock Inc. Now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after buying an additional 4,982,885 shares in the last quarter. GQG Partners LLC increased its stake in shares of Johnson & Johnson by 1,109.4% in the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after buying an additional 3,627,424 shares in the last quarter. State Street Corp increased its stake in shares of Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after buying an additional 2,492,359 shares in the last quarter. Finally, National Bank of Canada FI acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $286,371,000. 68.78% of the stock is owned by institutional investors.
A number of analysts have recently weighed in on the company. Raymond James raised their target price on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Morgan Stanley lowered their objective price on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Credit Suisse Group lifted their objective price on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Citigroup lowered their objective price on Johnson & Johnson from $210.00 to $205.00 in a research report on Tuesday, May 17th. Finally, Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their objective price for the stock from $180.00 to $183.00 in a research report on Wednesday, March 16th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $190.50.
Johnson & Johnson stock opened at $179.66 on Friday. The firm has a market capitalization of $472.76 billion, a P/E ratio of 24.21, a PEG ratio of 3.42 and a beta of 0.66. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The business has a 50-day moving average of $177.65 and a 200-day moving average of $173.20. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.60 by $0.07. The company had revenue of $23.43 billion during the quarter, compared to analyst estimates of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.59 EPS. Research analysts anticipate that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were given a dividend of $1.13 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s payout ratio is presently 60.92%.
In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Hait sold 29,699 shares of the business’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the completion of the sale, the insider now owns 80,236 shares in the company, valued at approximately $14,729,724.88. The disclosure for this sale can be found here. Insiders have sold a total of 78,161 shares of company stock worth $13,895,302 in the last quarter. 0.35% of the stock is currently owned by company insiders.
About Johnson & Johnson (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.